Akram Al-Makki
Overview
Explore the profile of Akram Al-Makki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gruver J, Al-Makki A, Shepler B
J Pharm Pharm Sci
. 2024 Jan;
26:11892.
PMID: 38173862
Hyperkalemia is a common electrolyte disorder in patients with chronic kidney disease (CKD) that increases in prevalence with the decline of glomerular fltration rate (GFR). Another risk of hyperkalemia is...
2.
Gunderman D, Fricker G, Kondury K, Moe S, Al-Makki A
J Gen Intern Med
. 2023 Sep;
38(16):3648-3650.
PMID: 37726646
No abstract available.
3.
Alasfar S, Zakaria W, Nasan K, Zanabli A, Al-Saghir F, Rifai A, et al.
Kidney Int
. 2023 May;
104(2):221-224.
PMID: 37187288
No abstract available.
4.
Sekkarie M, Al-Makki A, Kaysi S, Isreb M
Kidney Int
. 2022 Nov;
102(6):1427.
PMID: 36411020
No abstract available.
5.
Lin T, Al-Makki A, Shepler B
J Pharm Pharm Sci
. 2022 Jan;
25:77-83.
PMID: 35041802
Purpose: This narrative review explores the currently published studies that have evaluated tenapanor for the treatment of hyperphosphatemia in end-stage kidney disease (ESKD) patients on hemodialysis. This medication's new phosphate...
6.
Al-Makki A, DiPette D, Whelton P, Murad M, Mustafa R, Acharya S, et al.
Hypertension
. 2021 Nov;
79(1):293-301.
PMID: 34775787
Hypertension is a major cause of cardiovascular disease and deaths worldwide especially in low- and middle-income countries. Despite the availability of safe, well-tolerated, and cost-effective blood pressure (BP)-lowering therapies, <14%...
7.
8.
Sekkarie M, Murad L, Al-Makki A, Al-Saghir F, Rifai O, Isreb M
Semin Nephrol
. 2020 Aug;
40(4):354-362.
PMID: 32800286
Violent and protracted conflicts are disastrous to civilian populations and their health care systems. The complex requirements of caring for end-stage kidney disease (ESKD) dialysis patients in such contexts pose...
9.
Al-Makki A, Frost K, Yun S, Overholser B, Shepler B
J Pharm Pharm Sci
. 2019 Dec;
22(1):593-598.
PMID: 31804923
Purpose: The purpose of this retrospective cohort study was to measure the difference between cholecalciferol and ergocalciferol in their ability to effect vitamin D, parathyroid hormone (PTH), calcium, and phosphorous...
10.
Schuster A, Al-Makki A, Shepler B
Clin Ther
. 2019 Oct;
41(11):2416-2423.
PMID: 31601446
Purpose: Diabetic nephropathy (DN) is a major complication of diabetes. Paricalcitol is a vitamin D analog that is typically used for secondary hyperparathyroidism in patients with chronic kidney disease but...